CircPRDM2 Contributes to Doxorubicin Resistance of Osteosarcoma by Elevating EZH2 via Sponging miR-760
Jianjun Yuan,* Yan Liu,* Quan Zhang, Zhishuai Ren, Guang Li, Rong Tian Department of Spine Surgery, Tianjin Union Medical Center, Tianjin, 300121, People’s Republic of China*These authors contributed equally to this workCorrespondence: Rong TianDepartment of Spine Surgery, Tianjin Union Me...
Main Authors: | Yuan J, Liu Y, Zhang Q, Ren Z, Li G, Tian R |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-06-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/circprdm2-contributes-to-doxorubicin-resistance-of-osteosarcoma-by-ele-peer-reviewed-fulltext-article-CMAR |
Similar Items
-
EZH2: a novel target for cancer treatment
by: Ran Duan, et al.
Published: (2020-07-01) -
Role of EZH2 in epithelial ovarian cancer: from biological insights to therapeutic target
by: Hua eLi, et al.
Published: (2013-03-01) -
Role of EZH2 Inhibitor Combined with Gefitinib in EGFR-TKIs Resistant Lung Cancer Cells
by: Hao GONG, et al.
Published: (2019-05-01) -
Peritoneal Modulators of EZH2-miR-155 Cross-Talk in Endometriosis
by: Sarah Brunty, et al.
Published: (2021-03-01) -
EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?
by: Ke-Sin Yan, et al.
Published: (2017-05-01)